Spotlight Session - Biologics

(CSPOT17) A post-authorization safety study of golimumab in ulcerative colitis using the Spanish ENEIDA registry (MK8259-042)

(CSPOT19) Tree-based mining of real-world data for potential safety signals associated with the use of dupilumab in the United States (2017-2023)

(CSPOT20) Adherence Differences Between Self-Administered and Provider-Administered Biologics Among Patients with Rheumatoid Arthritis During the COVID-19 National Emergency

(CSPOT21) The Risk of Venous Thromboembolism in Two of the Most Common Inflammatory Skin Diseases - a Comparative Cohort Study Consisting of the Adult Populations of Atopic Dermatitis and Psoriasis in the Swedish Specialist Care

(CSPOT23) An Active Safety Surveillance Using Real-World Evidence (ASSURE) Approach to Pharmacovigilance Signal Evaluation: The case of infliximab and alternative autoimmune conditions

(CSPOT24) Trajectories of adherence to biological drugs in patients with inflammatory bowel diseases: the VALORE project